Responding more frequently to MiniMed Smart MDI alerts linked to better glucose outcomes for people with diabetes
Six-month randomized trial found 8.1 percentage points more Time in Range and 0.6 percentage points lower HbA1c among higher responders. NORTHRIDGE, Calif., Oct. 5, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED), a global leader in diabetes technology, today presented new clinical evidence...